Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina
PDF | HTML | How to cite
Metrics: PDF 1317 views | HTML 1574 views | ?
Ziliang Ye1,2, Haili Lu2, Qiang Su1, Xinhua Xian2 and Lang Li1
1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute, Nanning, Guangxi, China
2Guangxi Medical University, Nanning, Guangxi, China
Qiang Su, email: [email protected]
Lang Li, email: [email protected]
Keywords: ligustrazine, contrast-induced nephropathy, unstable angina
Received: May 04, 2017 Accepted: August 23, 2017 Published: September 28, 2017
Objective: Our purpose was to assess the effect of ligustrazine in the prevention of contrast-induced nephropathy (CIN) in patients with unstable angina (UA).
Methods: 148 patients with UA undergoing coronary angiography and/or percutaneous coronary intervention (PCI) were selected for observation; the patients were divided into a control group (group A, n=74) and a ligustrazine group (group B, n=74). Group A was given routine treatment, while group B was given routine treatment combined with ligustrazine. Serum creatinine (Scr), cystatin C and glomerular filtration rate (eGFR) concentrations were measured before and 1 day, 2 days and 3 days after treatment, and the incidence of contrast-induced nephropathy (CIN) and major cardiovascular events (MACE) were observed in both groups.
Results: The Scr, Cystatin C and eGRF levels in group B were better than in group A after 1 day (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively), 2 days (OR: 3.58, 95% CI: 2.41-4.92; OR: 2.92, 95% CI: 2.83-5.02; OR: 3.28, 95% CI: 3.24-5.14, respectively) and 3 days of treatment (OR: 3.26, 95% CI: 2.17-4.35; OR: 2.85, 95% CI: 2.26-4.02; OR: 3.19, 95% CI: 2.53-4.34, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) of group B were significantly lower than in group A (P<0.05).
Conclusions: Our study suggests that ligustrazine can reduce CIN and MACE in patients with UA when undergoing coronary angiography and/or PCI.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.